Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Industry Hails ‘Landmark’ Shortages Legislation

Bill Described As ‘Watershed Moment In The Security Of Medicine Supply’

Executive Summary

Legislation introduced in Australia aimed at mitigating shortages, that enshrines in law provisions of new five-year pharmaceutical industry pacts agreed by the government, has been hailed as a “landmark” development by the GBMA.

You may also be interested in...



Who’s Hired? Neuraxpharm, Lupin And ANI Announce Appointments

Neuraxpharm, Lupin and ANI have announced changes within their leadership teams, while board members have joined industry associations Medicines for Europe and Australia’s GBMA.

Australian Body Welcomes Passage Of Shortages Law

Legislation setting out measures to mitigate shortages in Australia has been passed by the country’s senate, incorporating into law key provisions of new five-year pact between the off-patent industry and the government.

What Aspects Will Give Humira Biosimilars The Edge In 2023?

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel